Pesquisar
Sangamo Therapeutics Inc
SGMOAdicionar à lista de desejos
0.178USD
0.0000.00%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
55.93MValor de mercado
PerdaP/L TTM
Mais detalhes de Sangamo Therapeutics Inc Empresa
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Informações de Sangamo Therapeutics Inc
Código da empresaSGMO
Nome da EmpresaSangamo Therapeutics Inc
Data de listagemApr 06, 2000
CEOMacrae (Alexander D)
Número de funcionários183
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 06
Endereço501 Canal Blvd.
CidadeRICHMOND
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94084
Telefone15109706000
Sitehttps://www.sangamo.com/
Código da empresaSGMO
Data de listagemApr 06, 2000
CEOMacrae (Alexander D)
Executivos da empresa Sangamo Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
572.66K
+55.96%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
114.13K
-61.18%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alexander D. Macrae, Ph.D.
Dr. Alexander D. Macrae, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert F. Carey
Mr. Robert F. Carey
Independent Director
Independent Director
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. James R. Meyers
Mr. James R. Meyers
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
572.66K
+55.96%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
114.13K
-61.18%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alexander D. Macrae, Ph.D.
Dr. Alexander D. Macrae, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Detalhamento da receita
FY2025
FY2024
FY2023
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
39.55M
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Vanguard Capital Management, LLC
3.07%
Two Sigma Investments, LP
2.20%
Renaissance Technologies LLC
2.04%
BlackRock Institutional Trust Company, N.A.
1.10%
Geode Capital Management, L.L.C.
0.93%
Outro
90.67%
Investidores
Investidores
Proporção
Vanguard Capital Management, LLC
3.07%
Two Sigma Investments, LP
2.20%
Renaissance Technologies LLC
2.04%
BlackRock Institutional Trust Company, N.A.
1.10%
Geode Capital Management, L.L.C.
0.93%
Outro
90.67%
Tipos de investidores
Investidores
Proporção
Investment Advisor
7.91%
Hedge Fund
4.86%
Investment Advisor/Hedge Fund
2.24%
Individual Investor
0.98%
Research Firm
0.95%
Corporation
0.78%
Pension Fund
0.06%
Venture Capital
0.04%
Outro
82.16%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
310
78.48M
18.95%
-38.54M
2025Q4
306
59.50M
16.66%
-53.91M
2025Q3
319
55.42M
16.47%
-39.56M
2025Q2
349
61.18M
25.54%
-60.51M
2025Q1
404
58.78M
24.86%
-65.68M
2024Q4
408
67.57M
32.39%
-54.70M
2024Q3
411
61.90M
29.72%
-75.37M
2024Q2
422
105.29M
52.02%
-52.38M
2024Q1
424
122.66M
61.96%
-20.13M
2023Q4
430
104.60M
58.76%
-36.84M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Two Sigma Investments, LP
9.12M
2.2%
+4.46M
+95.94%
Dec 31, 2025
Renaissance Technologies LLC
8.43M
2.04%
-1.75M
-17.21%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.54M
1.1%
-8.68K
-0.19%
Dec 31, 2025
Geode Capital Management, L.L.C.
3.87M
0.93%
+579.55K
+17.63%
Dec 31, 2025
Biogen Inc
3.25M
0.78%
-11.40M
-77.82%
Aug 14, 2024
UBS Financial Services, Inc.
1.02M
0.25%
-296.23K
-22.43%
Dec 31, 2025
Susquehanna International Group, LLP
2.14M
0.52%
-283.25K
-11.70%
Dec 31, 2025
Charles Schwab Investment Management, Inc.
1.71M
0.41%
+174.33K
+11.33%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.62%
iShares Neuroscience and Healthcare ETF
0.28%
Global X Genomics & Biotechnology ETF
0.2%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
State Street SPDR S&P Kensho New Econ Comp ETF
0%
State Street SPDR S&P Biotech ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.62%
iShares Neuroscience and Healthcare ETF
Proporção0.28%
Global X Genomics & Biotechnology ETF
Proporção0.2%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.02%
iShares Micro-Cap ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
Schwab U.S. Small-Cap ETF
Proporção0%
State Street SPDR S&P Kensho New Econ Comp ETF
Proporção0%
State Street SPDR S&P Biotech ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
